Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Deferred Taxes (2016 - 2025)

Sangamo Therapeutics (SGMO) has 5 years of Deferred Taxes data on record, last reported at $15000.0 in Q1 2025.

  • For Q1 2025, Deferred Taxes changed N/A year-over-year to $15000.0; the TTM value through Mar 2025 reached $15000.0, down 64.29%, while the annual FY2023 figure was -$6.3 million, N/A changed from the prior year.
  • Deferred Taxes reached $15000.0 in Q1 2025 per SGMO's latest filing, up from -$18000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $182000.0 in Q3 2023 and bottomed at -$140000.0 in Q4 2023.
  • Average Deferred Taxes over 3 years is $11400.0, with a median of $15000.0 recorded in 2025.
  • The widest YoY moves for Deferred Taxes: up 87.14% in 2024, down 90.11% in 2024.
  • A 3-year view of Deferred Taxes shows it stood at -$140000.0 in 2023, then surged by 87.14% to -$18000.0 in 2024, then surged by 183.33% to $15000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Deferred Taxes were $15000.0 in Q1 2025, -$18000.0 in Q4 2024, and $18000.0 in Q3 2024.